Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 20/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 20/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 20/20 | 0.58 |
| ▸ | CHRNB3 | Q05901 | 19/20 | 0.58 |
| ▸ | CHRNA6 | Q15825 | 19/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14709891 | 0.86 | CHRNB2 (0.43) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1978998 | 0.84 | CHRNB2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL30674446 | 0.80 | CHRNB2 (0.47) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1711178 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1711398 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL6863487 | 0.78 | CHRNB2 (0.59) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL12206738 | 0.78 | CHRNB2 (0.38) | CHRNB2CHRNA3CHRNA4CHRNB4 | |
| SCHEMBL26294765 | 0.78 | CHRNB2 (0.38) | CHRNB2CHRNA3CHRNA4CHRNB4 | |
| SCHEMBL10139547 | 0.78 | CHRNB2 (0.50) | CHRNB2CHRNA3CHRNA4CHRNB4 | |
| SCHEMBL13150517 | 0.77 | CHRNB2 (0.44) | CHRNB2CHRNA3CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802694-B2 | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands | TARGACEPT, INC. (US) | 2014-08-12 | — | — | US | claimed |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | TARGACEPT, INC. (US) | 2012-12-06 | — | — | US | claimed |
| EP-2509982-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Targacept, Inc. (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071758-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-06-16 | — | — | WO | claimed |
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8802694-B2 | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands | TARGACEPT, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802694-B2 | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands | TARGACEPT, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802694-B2 | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands | TARGACEPT, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | TARGACEPT, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | TARGACEPT, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | TARGACEPT, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2509982-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Targacept, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071758-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA3, CHRNA6 | CHRNB2 9/4885CHRNA3 2/4885CHRNA4 6/4885 |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | CHRNA3, CHRNA2, CHRNA6 | CHRNB2 9/4885CHRNA3 1/4885CHRNA4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.